US · MDXH
MDxHealth S.A.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Herstal 4040
- Website
- mdxhealth.com
Price · as of 2024-12-31
$2.06
Market cap 174.64M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $27.95 | +1,256.8% |
| Intrinsic Value(DCF) | $50.88 | +2,369.9% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.00 | $0.00 | |||
| 2012 | $0.00 | $0.00 | |||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $0.00 | $0.00 | |||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $0.00 | $0.00 | |||
| 2017 | $0.00 | $0.00 | |||
| 2018 | $0.00 | $115.83 | |||
| 2019 | $0.00 | $328.73 | |||
| 2020 | $0.00 | $0.00 | |||
| 2021 | $8.05 | $22.88 | $1.20 | $0.00 | $0.00 |
| 2022 | $2.95 | $23.82 | $9.83 | $0.00 | $0.00 |
| 2023 | $2.97 | $38.30 | $648.28 | $0.00 | $0.00 |
| 2024 | $1.49 | $27.95 | $361.73 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates MDxHealth S.A.'s (MDXH) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $27.95
- Current price
- $2.06
- AI upside
- +1,256.8%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$50.88
+2,369.9% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MDXH | MDxHealth S.A. | $2.06 | 174.64M | +1,257% | +2,370% | — | — | -2.93 | 4.89 | 0.81 | -3.90 | — | -1.18 | 61.23% | -27.45% | -42.28% | -224.25% | -91.23% | -17.26% | 4.05 | -3.24 | 1.57 | 1.44 | -0.60 | -3012.00% | 2829.00% | -2198.00% | -28.53% | -0.43 | -76.34% | 0.00% | 0.00% | 7.75% | -3.47 | -4.15 | 0.95 | -2.74 |
| ACRS | Aclaris Therapeutics, Inc… | $2.87 | 310.95M | +859% | -54% | — | +777% | -5.76 | 3.63 | 47.81 | -3.46 | — | 3.63 | 73.28% | -975.91% | -829.58% | -50.20% | 2416.55% | -34.10% | 0.00 | — | 5.28 | 5.28 | 0.31 | -6901.00% | -5819.00% | 13383.00% | -12.62% | -1.64 | 1494.19% | 0.00% | 0.00% | 0.00% | -2.92 | -4.72 | 28.46 | -5.14 |
| ASMB | Assembly Biosciences, Inc… | $29.84 | 256.95M | +2,630% | +9,923% | — | — | -1.66 | 2.00 | 2.34 | 0.93 | — | 2.00 | 100.00% | -159.26% | -140.87% | -107.92% | 55.92% | -31.39% | 0.09 | — | 2.42 | 2.35 | 0.78 | -5000.00% | 29816.00% | -32743.00% | -76.60% | -1.07 | 62.97% | 0.00% | 0.00% | 26.59% | 0.93 | 0.83 | -1.48 | -9.57 |
| IMRX | Immuneering Corporation | $4.99 | 181.15M | — | — | — | — | -0.75 | 1.10 | — | -0.21 | -8.77 | 1.33 | 0.00% | — | — | -92.51% | -682.42% | -78.61% | 0.10 | — | 5.28 | 4.82 | 0.50 | 851.00% | — | 1171.00% | -120.87% | -7.33 | -586.70% | 0.00% | 0.00% | 0.00% | -0.21 | -0.25 | — | -6.82 |
| NEO | NeoGenomics, Inc. | $9.83 | 255.21M | +138% | -61% | — | — | -2.25 | 0.29 | 0.33 | 318.65 | -6.35 | 9.47 | 38.85% | -9.09% | -14.85% | -12.42% | -5.70% | -7.21% | 0.56 | -17.61 | 4.26 | 3.61 | 179.17 | 3548.00% | 1011.00% | -3602.00% | -8.95% | 0.06 | -1.92% | 0.00% | 0.00% | 0.00% | -8.41 | -25.53 | 0.76 | 0.46 |
| QTRX | Quanterix Corporation | $6.55 | 305.96M | +237% | -22% | -45% | — | -7.37 | 0.86 | 2.10 | -0.73 | -45.26 | 0.87 | 59.89% | -38.85% | -28.45% | -11.33% | -70.92% | -9.23% | 0.11 | — | 8.66 | 7.65 | 0.44 | 1628.00% | 1180.00% | 6982.00% | -13.57% | -0.84 | -51.94% | 0.00% | 0.00% | 0.00% | -0.61 | -0.83 | 0.24 | 1.46 |
| SI | SHOULDER INNOVATIONS, INC… | $13.56 | 279.36M | — | — | — | — | — | — | — | — | — | — | 76.97% | -46.34% | -49.39% | -57.30% | -81.73% | -32.08% | 0.74 | -11.13 | 4.59 | 2.64 | -0.71 | 2222.00% | 6407.00% | 1426.00% | — | -1.85 | -101.28% | — | 0.00% | — | — | — | — | — |
| SNWV | SANUWAVE Health, Inc. | $24.33 | 208.62M | +2,106% | +2,696% | — | — | -4.13 | -10.18 | 3.97 | -8.74 | — | -5.46 | 75.23% | 16.60% | -96.13% | 112.25% | -90.44% | -119.43% | -2.00 | 0.40 | 0.43 | 0.32 | -0.92 | -4233.00% | 5999.00% | -14330.00% | 1.52% | 0.06 | -32.81% | 0.00% | 0.00% | 10.35% | 26.71 | 73.63 | 4.43 | -9.15 |
| XGN | Exagen Inc. | $3.62 | 82.04M | +641% | +1,119% | — | — | -3.89 | 6.16 | 1.06 | -5.36 | — | 6.16 | 59.51% | -24.51% | -27.17% | -93.78% | -136.76% | -29.74% | 2.41 | -6.10 | 2.70 | 2.21 | -0.09 | -3806.00% | 589.00% | -978.00% | -23.46% | -0.98 | -138.35% | 0.00% | 0.00% | 0.00% | -4.38 | -4.33 | 1.07 | -7.36 |
| ZURA | Zura Bio Limited | $6.62 | 430.45M | — | — | — | — | -1.81 | 0.64 | — | 1.48 | — | 0.64 | 0.00% | — | — | -50.84% | 157.33% | -37.38% | 0.00 | — | 9.16 | 9.04 | 3.20 | -7129.00% | — | 2211.00% | -29.76% | -1.44 | 80.25% | 0.00% | 0.00% | 81.08% | 1.48 | 2.91 | — | 1.74 |
About MDxHealth S.A.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
- CEO
- Michael K. McGarrity
- Employees
- 312
- Beta
- 0.38
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($50.88 ÷ $2.06) − 1 = +2,369.9% (DCF, example).